Nanobiotix (NASDAQ: NBTX) — Perfil da empresa, notícias e dados financeiros
Nanobiotix revolutionizes cancer treatment through nanomedicine and pioneers radioenhancers for radiotherapy.

Nanobiotix
Nanobiotix (EURONEXT:NANO), (NASDAQ:NBTX) is a company dedicated to revolutionizing cancer treatment through its pioneering work in nanomedicine. Its primary focus lies in developing and commercializing novel therapeutics based on the innovative use of nanoparticles to directly target and destroy cancerous cells, while minimizing damage to healthy tissue. Nanobiotix’s flagship project, NBTXR3, is a first-in-class radioenhancer designed to increase the efficacy of radiotherapy, a cornerstone treatment for cancer. The company's objectives are centered on advancing the clinical development of its product pipeline, securing regulatory approvals, and establishing partnerships to ensure global access to its technologies.
Resumo
Operações
Produtos e/ou serviços de Nanobiotix
- NBTXR3, a radioenhancer designed to increase the efficacy of radiotherapy in various cancer types.
- Clinical trials assessing NBTXR3's potential with immune checkpoint inhibitors for advanced solid tumors.
- Research into combining NBTXR3 with chemotherapy for enhanced treatment outcomes.
- Development of nanoparticle-based solutions for targeted cancer therapy.
- Investigations into NBTXR3's application in head and neck cancer treatment, aiming to improve patient survival.
- Exploration of NBTXR3's efficacy in soft tissue sarcoma, focusing on limb preservation and reducing amputation rates.
equipe executiva do Nanobiotix
- Laurent LevyCo-Founder, President of the Executive Board & CEO
- Anne-Juliette HermantChief People Officer & Member of Executive Board
- Louis KayitalireChief Medical Officer & Member of Executive Board
- Earl J. BergeyCo-Founder
- Arnd ChristCFO & Member of Executive Board
- Brandon OwensVP of Strategic Marketing & Corporate Communication
- Margaret GalluzziVP & Global Head of Clinical Operations
- Leonard A. FarberChief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board
- Anne-Sophie LariviereChief Product Innovation & Delivery Officer
Últimas notícias sobre a Nanobiotix
Nanobiotix reports 79% one-year control with JNJ-1900
United StatesNanobiotix radiographic data shows high response rates in lung cancer trial
United StatesNanobiotix Nanoprimer enhances LNP-DNA delivery, reduces liver toxicity in preclinical trials
United StatesNanobiotix lung cancer trial data shows 71% response rate at ELCC
United States
Principais indicadores financeiros
Resultados divulgados pela Nanobiotix, em EUR.
- Cap. de mercado
- 1,8 bi
- Receita (TTM)
- 11,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 29,6 mi | -10,8 mi | -24 mi | |
| -7,2 mi | -68,4 mi | -68,1 mi | |
| 36,2 mi | -26,8 mi | -39,7 mi | |
| 4,8 mi | -46,7 mi | -57 mi |